Skip to main content

Table 2 Descriptive report of different treatment regimens’ effect on COVID-19 transplant patients' outcome

From: Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?

Drugs

Length of stay; mean ± SEM*

O2 therapy (%)

Mortality (%)

Intensive care unit stay

Hospital

Mechanical ventilation used

Mechanical ventilation not used

Yes

No

Hydroxychloroquine

No

16.22 ± 9.87

27.21 ± 15.32

11 (19)

155 (83)

8 (40)

158 (70)

Yes

20.98 ± 10.09

30.87 ± 15

48 (81)

31 (17)

12 (60)

67 (30)

Interferon

No

17.70 ± 15.44

26.59 ± 13.90

49 (83)

41 (48)

11 (55)

79 (35)

Yes

22.88 ± 16.79

31.11 ± 14.00

10 (17)

45 (52)

9 (45)

46 (20)

Lopinavir/Ritonavir

No

20.19 + 16.60

24.40 ± 14.00

15 (25)

40 (47)

1 (5)

54 (24)

Yes

27.60 ± 15.43

34.30 ± 16.99

44 (75)

46 (53)

19 (95)

71 (32)

Remdesivir

No

24.31 ± 12.41

34.45 ± 13.76

46 (78)

97 (52)

10 (50)

133 (59)

Yes

18.91 ± 10.00

27.00 ± 11.65

13 (22)

89 (48)

10 (50)

92 (41)

Tocilizumab

No

23.30 ± 13.13

31.11 ± 12.00

49 (82)

136 (74)

13 (65)

172 (76)

Yes

18.83 ± 10.90

28.00 ± 14.10

11 (18)

49 (26)

7 (35)

53 (24)

Dexamethasone or High dose methylprednisolone

No

24.33 ± 13.00

33.30 ± 13.00

45 (76)

64 (34)

9 (45)

100 (44)

Yes

19.77 ± 12.00

29.70 ± 11.10

14 (24)

122 (66)

11 (55)

125 (56)

  1. *Standard error of the mean